Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.59 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.59 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21674204 | 0.88 | MEN1 (0.57) | NPC1RAB9ASMN1; SMN2PTPN1MEN1 | |
| SCHEMBL2021051 | 0.88 | MEN1 (0.57) | NPC1RAB9ASMN1; SMN2PTPN1MEN1 | |
| SCHEMBL14424704 | 0.87 | NPC1 (0.69) | NPC1RAB9AATMSMN1; SMN2MAPK1 | |
| SCHEMBL4611024 | 0.87 | NPC1 (0.69) | NPC1RAB9AATMSMN1; SMN2MAPK1 | |
| SCHEMBL4608963 | 0.87 | NPC1 (0.69) | NPC1RAB9AATMSMN1; SMN2MAPK1 | |
| SCHEMBL200 | 0.87 | LOXL2 (0.66) | NPC1SMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL6263820 | 0.87 | NPC1 (0.83) | NPC1RAB9AATMSMN1; SMN2MAPK1 | |
| SCHEMBL8660366 | 0.87 | NPC1 (0.83) | NPC1RAB9AATMSMN1; SMN2MAPK1 | |
| SCHEMBL4050326 | 0.86 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2MAPK1MEN1 | |
| Phosphine SCHEMBL10705044 | 0.85 | LOXL2 (0.63) | NPC1RAB9ASMN1; SMN2MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678794-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1817296-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | NPC1 2449/4885RAB9A 4407/4885ATM 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.